NDAORALTABLET
Approved
Feb 2011
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
ZIDOVUDINE (zidovudine) by Matrix Surgical USA is nucleoside reverse transcriptase inhibitors [moa]. First approved in 2011.
Drug data last refreshed 11h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Zidovudine is an oral nucleoside reverse transcriptase inhibitor (NRTI) approved for HIV treatment. It works by inhibiting reverse transcriptase, the enzyme HIV uses to replicate. This drug represents a foundational antiretroviral therapy class that has been central to HIV management for decades.
LOE Approaching
With LOE approaching and moderate competitive pressure (30% competitive index), this product is in transition phase; expect smaller, focused teams managing lifecycle extension strategies rather than growth initiatives.
Mechanism of Action
Nucleoside Reverse Transcriptase Inhibitors
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Suppression of Cytomegalovirus Retinitis Utilizing High Dose Intravenous Acyclovir and Oral Zidovudine in Patients With AIDS
25 enrolled
Cytomegalovirus RetinitisHIV Infections
A Phase I Study to Evaluate the Safety and Toxicity of the Combination of Zidovudine and 2',3'-Dideoxyinosine (Didanosine) in Children With HIV Infection
85 enrolled
HIV Infections
A Study of Zidovudine Plus Interleukin-2 in HIV-Infected Patients Who Have No Symptoms of Infection But Who Have Tender Lymph Nodes
30 enrolled
HIV Infections
Intracellular Pharmacokinetics of Zidovudine Triphosphate in Maternal and Infant Cord Blood Mononuclear Cells.
24 enrolled
HIV InfectionsPregnancy
A Phase III Study to Evaluate the Safety, Tolerance, and Efficacy of Early Treatment With Zidovudine (AZT) in Asymptomatic Infants With HIV Infection
400 enrolled
HIV Infections
Worked on ZIDOVUDINE at Matrix Surgical USA? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.